Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels.
I. Introduction
A NGIOGENESIS IS DEFINED as the development of new blood vessels from preexisting vessels, and it is a crucial process in normal physiology (1) . Thus, angiogenAbbreviations: CAM, Chorioallantoic membrane; EGF, epidermal growth factor; ER, estrogen receptor; F8, factor eight-related antigen; FGF, fibroblast growth factor; FGFR, FGF receptor; FSC, folliculostellate cells; HGF, hepatocyte growth factor; HIF, hypoxia inducible factor; HRE, hypoxia response element; HUVEC, human umbilical vein endothelial cell(s); IGFBP, IGF binding protein; ISH, in situ hybridization; LIF, leukemia inhibitory factor; LOH, loss of heterozygosity; MEN, multiple endocrine neoplasia; MMP, matrix metalloproteinase; MT1-MMP, membrane type 1 MMP; MVD, microvascular density; NF-1, neurofibromatosis type 1; NFA, nonfunctioning adenoma or tumor(s); PACAP, pituitary adenylate cyclase activating peptide; PAI-1, plasminogen activator inhibitor 1; PRL, prolactin; PTTG, pituitary tumor-transforming gene; TIMP, tissue inhibitors of metalloproteinase; TSP, thrombospondin; UEA1, ulex europaeus agglutinin 1; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VHL, Von Hippel Lindau.
esis plays an essential role in physiological processes such as embryonic development, wound healing, and the normal menstrual cycle (2, 3) . It is however also an important pathogenic process in several diseases such as atherosclerosis (4) , arthritis (5) , diabetic retinopathy (6) , and psoriasis (7) .
A major interest has been the relationship of pathological angiogenesis and its role in tumor biology (8) . On the basis of experiments that showed that tumors implanted into isolated perfused organs failed to develop, whereas the same tumors implanted within 6 mm of blood vessels not only induced angiogenesis but also both grew and metastasized (9, 10), Folkman (11) proposed that solid tumors are dependent on the process of angiogenesis for growth beyond a few millimeters in size and that increased tumor diameter required a corresponding increase in vascularization.
Angiogenesis (measured as tumor microvessel density) correlates with tumor behavior. In many human tumors, including breast, bladder, and stomach, increased angiogenesis has been shown to be associated with the development of metastases (12, 13) , poor prognosis (14, 15), and reduced survival (16, 17) .
Endocrine organs are very vascular, with fenestrated epithelium lining the blood vessels, which allows easy transfer of substances across the permeable vessel wall (18, 19) . The blood supply is clearly essential for normal metabolic and endocrine functions. Complex feedback loops whereby differences in the serum concentration of various factors lead to alteration in hormonal secretion are essential for endocrine function. The necessity for rapid and tight regulation of these systems, frequently over a very small range of hormone concentrations, clearly requires an efficient blood supply. The purpose of this review is to explore current knowledge regarding angiogenesis in endocrine tumors.
Although the process of angiogenesis has been mainly studied in the context of malignant tumors, precancer has also been associated with increased angiogenic growth factor expression and increased vascularity when compared with nonneoplastic host tissue. Premalignant lesions are more vascular than normal tissue, and precarcinoma of the cervix and breast exhibit increased microvascular density (MVD) (20 -22) . Studies using RT-PCR and in situ hybridization (ISH) for the proangiogenic growth factor vascular endothelial growth factor (VEGF) in colonic tissues ranging from normal colon to invasive colorectal tumors show increased VEGF expression in the premalignant phase (23). Histologically, normal lobules derived from breast tissue harboring cancer are more angiogenic than lobules derived from breasts without cancer (24). Transgenic mice with an oncogene in the pancreatic ␤-cells demonstrate increased angiogenesis in hyperplastic islets before development of frank neoplastic change (25). Inhibitors of angiogenesis such as angiostatin and endostatin reduce tumor growth if administered at this early stage, suggesting that increasing angiogenesis is important to tumor progression (26).
II. Mechanism of Angiogenesis
Angiogenesis is a multistep process, involving both the endothelium and the extracellular matrix (1) . After a stimulatory signal (such as a specific growth factor), activated endothelial cells release proteases (such as plasminogen activator), which lead to degradation of the extracellular matrix surrounding the vessel (27), followed by endothelial migration and proliferation. Endothelial cells are reorganized into a tubular structure, followed by fusion with other newly formed vessels, leading eventually to an anastomotic network (28).
The events that occur during development of an angiogenic phenotype are complex, involving stimulation by different proangiogenic growth factors and reduction in inhibitors of angiogenesis. The process involves an interaction between tumor cells, endothelial cells, macrophages, fibroblasts, and the extracellular matrix, all of which are capable of releasing factors influencing the angiogenesis mechanism. It is the net balance of proangiogenic factors and inhibitors of angiogenesis that determines the final angiogenic phenotype of the tumor.
Adult endothelial cells are usually quiescent, but may be stimulated to enter the cell cycle and develop into new capillaries. The switch concept describes the process whereby angiogenesis is activated (29). An understanding of the mechanism of this angiogenic switch in tumors may lead to further understanding of specific determinants of tumor behavior including invasion, malignancy, and metastasis. Studies in transgenic mice, in which tumor development progresses through distinct stages, have demonstrated that the switch to an angiogenic phenotype occurs at an early stage in tumor development and is potentially rate-limiting for subsequent tumor growth (25, 29) .
Mechanisms subserving the angiogenic switch relate to a balance of proangiogenic and inhibitory stimuli. Angiogenesis inducers include VEGF and basic fibroblast growth factor (FGF-2), whereas more recently endogenous angiogenesis inhibitors have been described. These latter are often cleaved products of other larger proteins that are not themselves inhibitors. For example, angiostatin is a cleaved product of plasminogen, and endostatin arises from collagen XVIII. Control of proteases and the cleavage process is still not elucidated, but the system is usually effective in inhibiting angiogenesis, as exemplified in pancreatic islets in which VEGF and FGF expression is constitutive but angiogenesis does not normally occur (30). Negative regulators may be particularly important in endocrine organs that are very vascular, to maintain a quiescent endothelium, and rather than increased inducers of angiogenesis, down-regulation of inhibitor production may be required to activate the angiogenic switch (29) (Fig. 1) .
A. Proangiogenic growth factors
Endogenous proangiogenic factors include VEGF and FGF-2, TGF-␣, proliferin, platelet-derived growth factor, IL-8, and hepatocyte growth factor (HGF) 3. Angiogenesis may often involve several different proangiogenic growth factors (VEGF A, B, C, and D; FGF; TGF ␤1; placenta growth factor; angiopoietins, etc.) (31), but different lines of evidence show that VEGF plays a key role in both physiological and pathological angiogenesis (for review, see Ref. 32) .
FGFs were the first angiogenic factors discovered, and they are probably of importance when the tumor becomes large, degrades the extracellular matrix in which FGF is sequestered, and acts through the high-affinity cell-surface tyrosine kinase FGF receptors (FGFR-1 to FGFR-4) (for review, see Ref. 33 ). There are currently 20 described distinct FGFs of which FGF-1, FGF-2, and to a lesser extent FGF-3, FGF-4, FGF-5, and FGF-7 have been shown to possess proangiogenic activity (33, 34) . Alternate splicing of the FGFR genes and/or expression of the different FGFR genes themselves leads to different forms of FGFR expression and specificity for different FGFs (33). VEGF mRNA is up-regulated in virtually every tumor type examined, and in all of these cases VEGF mRNA is invariably expressed in tumor cells (35) (36) (37) (38) . Other experiments have shown that the stroma around the tumor may also be an important source of VEGF (39). Immunohistochemistry demonstrates VEGF expression not only in tumor cells but also in the vasculature of these tumors, showing that VEGF is secreted as a paracrine mediator that localizes in target cells (36, 40) . High VEGF expression correlates with poor prognosis in breast cancer and non-small cell lung cancer (31, 40, 41).
After the discovery of VEGF, other VEGF-related genes have been identified, encoding placental growth factor and VEGF-B, -C, and -D (38). These demonstrate variable structural homology to VEGF but have different receptor specificities (Table 1) . VEGF-B is mainly found in muscle and myocardium but not endothelial cells and signals through VEGF receptor (VEGFR)-1 (42, 43). VEGF-C and VEGF-D signal through the VEGFR-2 and VEGFR-3 to stimulate lymphangiogenesis (44 -47). All three VEGF receptors are characterized by seven extracellular Ig homology domains in which the second and third domains are essential for ligand binding and the fourth to seventh are essential for receptor dimerization (38, 48, 49) . Signal transduction involves receptor dimerization and activation of tyrosine kinase (50).
Knockout studies in mice demonstrate that Flt-1 (Ϫ/Ϫ) (VEGFR-1) mice die at embryonic d 8.5 due to disorganization and overgrowth of endothelial cells (51). KDR (Ϫ/Ϫ) (VEGFR-2) knockout mice are also lethal at embryonic d 8.5 due to the lack of blood vessel development as well as inadequate hemopoiesis (52). VEGFR-3-deficient embryos die due to defective vascular remodeling before lymphatic development (53).
High-affinity, anti-VEGF antibodies have demonstrated a direct role for VEGF in tumor development. Potent inhibition of growth of three human tumor cell lines injected into nude mice (SK-LMS-1 leiomyosarcoma, G55 glioblastoma multiforme, and A673 rhabdomyosarcoma) was shown after antibody administration of 70 -95% (54). VEGF monoclonal antibody administration to tumor-bearing athymic mice leads to a reduction in colon cancer metastases and tumor growth (55, 56). Anti-VEGF monoclonal antibodies are also able to reduce subsequent growth of established tumors (57).
VEGF signals through two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR) ( Table 1) , expressed mainly on endothelial cells; VEGFR-2 is responsible for signaling, whereas VEGFR-1 may play a regulatory role (1) . A third VEGF receptor (VEGFR-3) is found in lymphatic endothelium, which binds other members of the VEGF family (VEGF-C and VEGF-D) (58 -60). Recombinant soluble VEGFR-1 or VEGFR-2 inhibits angiogenesis in the retina, corpus luteum, and tumors (61-63), whereas expression of a dominant negative VEGFR-2 mutant using a retrovirus inhibits signaling through the receptor and suppresses growth of tumors such as glioblastoma multiforme in vivo (64, 65). Expression of a soluble VEGFR-3 has been shown to inhibit lymphangiogenesis in mouse embryos (47).
The human VEGF gene is localized to 6p21.3, and alternative exon splicing generates four different isoforms of VEGF: VEGF 121, 165, 189, and 206 (66) . Regulation of VEGF gene expression occurs via several different mechanisms, including hypoxia, growth factors, and cytokines (66). The hypoxic signal is mediated via hypoxia inducible factor (HIF)-1, a heterodimer consisting of a constitutively expressed HIF-1 ␤-subunit, (HIF-1␤) and an oxygen and growth factor regulated HIF-1 ␣-subunit (HIF-1␣). HIF-1␣ is usually unstable in the presence of oxygen and subject to oxygen-dependent ubiquination and proteasomal degradation, whereas during states of hypoxia, HIF-1␣ is stable (67). The dimer HIF-1 binds to the hypoxia response element (HRE) within the VEGF promoter and leads to VEGF tran- scription (68). Another transcription factor, HIF-2␣, also accumulates during hypoxia and binds to a ␤-subunit to form an HIF-1 complex, activating HREs, leading to increased VEGF transcription (69, 70), and undergoing oxygen-dependent degradation. HREs are also found within genes of the glycolytic pathway and the erythropoietin gene leading to oxygen regulation of glycolysis and red cell formation (71). In vitro HIF-defective tumors do not show increased VEGF around areas of necrosis and are less vascularized (72).
Other proangiogenic growth factors and cytokines also up-regulate VEGF mRNA expression, including epidermal growth factor (EGF), TGF-␤, FGF, IL-1, and IGF-I (73-77). VEGF may therefore also act as a paracrine mediator for other angiogenic factors. Cell density also determines VEGF expression independent of the presence of hypoxia (78).
The angiopoietins are another family of angiogenic growth factors that signal through the Tie family of receptors (79). Ang-1 and Ang-2 are stimulatory and inhibitory ligands, respectively, at the Tie-2 receptor and important in the female reproductive cycle as well as tumor development (80, 81) . Recent studies have demonstrated that the angiopoietins and VEGF in combination may fine-tune the process of angiogenesis (82).
A link between hormonal stimulation and increased angiogenesis has recently been elegantly demonstrated (83, 84) ( Fig. 2) whereby castration-induced regression of prostate vasculature was reversed by testosterone-dependent angiogenic factors. Although this increase in angiogenesis occurred in the absence of androgen receptors on endothelial cells, the identity of these angiogenic factors responsive to increased testosterone is as yet unknown, but likely includes VEGF.
B. Measurement of angiogenesis
Measurement of vascular density has been used to investigate angiogenesis in different tumors. This has been shown to be a useful quantitative method of assessing angiogenesis, despite the fact that angiogenesis is a dynamic process and MVD is a static measure. Microvessel density correlates with the concentration and expression of proangiogenic growth factors, e.g., FGF-2 and VEGF (85). MVD is also associated with enzymes involved in the early stages of angiogenesis such as plasminogen activator inhibitor 1 (PAI-1) (86). Importantly, MVD has been shown to be closely related to parameters of angiogenesis-dependent tumor behavior such as tumor growth and metastasis in breast, lung, and urogenital cancers (87).
Vascular density of different tumors has been assessed by counting vessels labeled using immunohistochemistry with antibodies to different endothelial markers on both frozen and paraffin-embedded sections. Antibodies that are most commonly used are directed against the endothelial antigens factor eight-related antigen (F8), CD31 (platelet endothelial cell adhesion molecule), CD34, and the lectin ulex europaeus agglutinin 1 (UEA1). These markers differ in their sensitivity for detection of endothelium (88, 89). CD31 and CD34 are the most sensitive and specific markers currently available for use on paraffin sections, although other markers may be easier to use because of practical difficulties with antigen retrieval (87). Different antibodies demonstrate varying sensitivities for detection of endothelium. F8 stains large vessels but does not label smaller microvessels (90). CD31 stains microvessels, but antigen loss can make this reagent unreliable in paraffin-embedded tissue; UEA1 stains all microvessels, but also stains the Golgi in some neoplastic cells (87, 88, 91). Choice of technique may therefore influence the results of MVD measurement.
The use of these markers reflects total vascular density, and new markers being developed are more specific for activated endothelium, but their disadvantage is that, at present, most are only effective when used on frozen tissue. They may, however, be useful to assess specific targets for therapy, e.g., new vessels or the degree of vascular remodeling. These include Tie 2/Tek, which recognizes an endothelial tyrosine kinase (92, 93); E-9, which recognizes endoglin, which is expressed on vascular cells from tumors and inflamed organs (94); and TEC-11, which recognizes a different epitope of endoglin (95). Tumor angiogenesis may also be measured in vivo by magnetic resonance imaging using a contrast agent targeted to the ␣V␤3 integrin, which is more strongly expressed on blood vessels undergoing angiogenesis and may play a role in extracellular matrix adherence during angiogenesis (96). The use of the LH39 antibody recognizing an epitope found only in mature vessels and comparison with vascular counts using CD31, which recognizes both mature and newly formed vessels, allows a measurement of active vascular remodeling rather than a static vessel count. This vascular maturation index correlates well with tumor stage and prognosis in non-small cell lung and breast cancer (97, 98).
There are several methods for quantifying microvessel counts. The original technique described the selection of the most highly vascular areas (hot spots) and counting of individual microvessels (12) . The rationale for locating the most vascular area hot spot is based on the fact that tumor behavior is likely to be related to the most vascular area of the tumor (87). Other described techniques are an overall semiquantitative grading technique, Chalkley counting using a microscope eyepiece containing a graticule containing 25 randomly positioned dots (99), and computerized image analysis (87, 100). Clearly the choice of quantification method introduces another important variable when using MVD as a reflection of angiogenesis.
The accuracy of these techniques depends mainly on the correct localization of the hot spot in addition to whether a representative block of tissue is chosen. Despite these potential problems, microvessel counts derived from all techniques have been shown to correlate with tumor prognosis and behavior (12, 15, 87) .
C. Influence of hormones on angiogenesis and VEGF
The close relationship between endocrine function and angiogenesis is demonstrated during physiological processes such as the normal menstrual cycle, but also within pathological processes such as the regression in prostate vasculature after castration and the increase in vascularity of the thyroid gland during goiter development. Table 2A summarizes the in vitro and in vivo effects of hormones on MVD/angiogenesis and/or VEGF production. Most hormones increase angiogenesis, except for glucocorticoids, which reduce VEGF expression.
The mechanism of hormonal effects on angiogenesis has been elucidated for estrogen and VEGF. Estrogen [bound to either estrogen receptor (ER)␣ or ER␤] can lead to either increased or reduced VEGF gene transcription, depending on whether the ER binds to the 3Ј or 5Ј untranslated region of the VEGF gene (103). The proangiogenic effects of GH and IGF-I are shown to depend at least in part on the interaction of IGF-I with VEGF activation of p44/42 MAPK (126). Administration of an IGF-I receptor antagonist to bovine retinal vascular endothelial cells reduces VEGF-induced MAPK activation by 50%. The proangiogenic effects of GH and IGF-I explain why retinopathy may worsen when patients with diabetes are commenced on insulin treatment, leading to an increase in IGF-I. However, GH-overexpressing mice do not show increased angiogenesis (122), and patients with acromegaly do not demonstrate an increased incidence of retinopathy, suggesting a permissive rather than direct stimulatory effect of GH/IGF-I on angiogenesis.
In Graves' disease, consistent with the stimulatory effect of TSH receptor antibodies on thyroid function itself, these antibodies also increase angiogenic factors (120). TSH stimulation of cultured thyrocytes was shown in a biological assay to cause endothelial cell proliferation (119).
D. Inhibitors of angiogenesis
The recognition of the therapeutic potential of inhibiting angiogenesis for treating tumors and other angiogenesisdependent conditions has led to the study of several agents that act at different stages of the angiogenesis pathway (140 -142). The control of physiological angiogenesis and maintenance of homeostasis have also led to the investigation of endogenous angiogenesis inhibitors. It has been recognized for many years that tumor (e.g., breast) metastases may remain dormant and also, curiously, that removal of a primary tumor may be followed by the rapid appearance of metastases.
Studies in a Lewis lung carcinoma mouse model have provided useful information on the mechanism of inhibition of angiogenesis. Removal of the primary tumor leads to rapid growth of tumor metastases (143). Serum and urine derived from mice bearing tumors were shown to inhibit endothelial proliferation (144). This endogenous inhibitor, termed angiostatin, was shown to be a cleaved product of plasminogen and inhibited angiogenesis and metastasis growth in vivo, although intact plasminogen lacked this activity (144). Further investigation of the behavior of dormant metastases showed that although cell proliferation of growing and dormant metastases was not different, metastases remained dormant due to a marked increase in apoptosis (145). Administration of angiostatin leads to inhibition of primary human and murine tumor growth in mice (146). The mechanism of generation of angiostatin from plasminogen has been investigated. Prostate carcinoma cells were shown to possess enzyme activity that cleaved plasminogen to active angiostatin (147, 148). The mechanism whereby angiostatin inhibits angiogenesis likely involves binding to ATP synthase in endothelial cells (149). Angiostatin administration using an adenovirus vector to a glioma tumor model (150), liposomes to a transgenic model of breast cancer (151), and sc to mice with colorectal tumors (152) leads to inhibition of tumor growth or reduction in metastases.
Endostatin, another cleavage product that acts as an endogenous angiogenesis inhibitor, was discovered from a murine hemangioendothelioma (153). This proteolytic fragment of collagen XVIII leads to inhibition of endothelial proliferation as well as increased tumor cell apoptosis leading to metastatic regression and dormancy of tumors.
Thrombospondin (TSP)1 and TSP2 are glycoproteins located within the extracellular matrix and possessing antiangiogenic activity (154). TSP1 suppresses vascular growth in vitro and in vivo, in both normal tissue and tumors (155). Expression of wt p53 has been associated with TSP1 expression providing a link between tumor suppressor gene expression and control of angiogenesis (156).
Of relevance to endocrine glands, somatostatin analogs (157-161) have been shown to possess inhibitory effects on angiogenesis. An endogenous substance, the 16-kDa fragment of prolactin (PRL), has also been demonstrated to possess angioinhibitory effects (162, 167).
Somatostatin analogs.
Using the chick chorioallantoic membrane (CAM), which allows visualization of changes in angiogenesis, the implantation of discs containing the somatostatin analog SMS 201-995 (octreotide) inhibited blood vessel growth in a dose-dependent fashion in vitro (157). Further studies using different somatostatin analogs demonstrated that the inhibition of angiogenesis was dependent on the structure of the molecule (158). Some analogs failed to inhibit angiogenesis. The mechanism for this effect, however, is not known but may involve inhibition of endothelial cell proliferation, although the precise somatostatin receptor involved is unknown. In vivo studies confirm that octreotide inhibits proliferation of human umbilical vein endothelial cells (HUVEC) (159). Studies of the antiangiogenic effect of somatostatin analogs in endocrine tumors have not been reported. Table  2B ). The PRL molecule has been shown to give rise to a cleaved product, the 16-kDa fragment, which inhibits angiogenesis (167). There is evidence to suggest that the cleaving enzyme may be cathepsin D (168). The 16-kDa fragment has been shown in bioassays to have approximately 10% of the lactogenic effects of total PRL and 65% of the mitogenic activity (169). The full-length PRL molecule in contrast has been shown in the CAM assay to have proangiogenic effects, although it did not have demonstrable effects on angiogenesis in another in vivo assay (corneal angiogenesis) (162). These differences may be due to the maturity of the vessels studied.
16-kDa PRL and other members of the PRL/GH family (
The 16-kDa PRL fragment generated by rat mammary gland cleavage inhibits growth of bovine brain and adrenal cortex endothelial cells in vitro (167). Cleavage and reduction of recombinant human PRL also generates a 16-kDa PRL molecule that inhibits basal and FGF-2-and VEGF-stimulated endothelial proliferation in vitro using cultured endo- thelial cells and in an in vivo assay using the chick (CAM) (164). A 14-kDa PRL fragment that inhibits angiogenesis has been demonstrated with similar activity to 16-kDa PRL (170) . The full-length PRL molecule was ineffective in inhibiting angiogenesis even at high concentrations, suggesting that the 16-kDa fragment was not acting through the conventional PRL receptor. Studies in bovine brain endothelial cells demonstrated the presence of a high-affinity saturable specific 16-kDa PRL receptor (171) . The mechanism of action of 16-kDa PRL has been shown to involve inhibition of VEGF and FGF-2 RAS activation and MAPK signaling (172, 173) . PRL fragments with angioinhibitory activity have been demonstrated in both the posterior and anterior pituitary gland of rat (170) , mice (174, 175) , and humans (176) .
Other members of the PRL/GH family and their respective cleaved fragments have also been shown in vitro and in vivo to exert opposing angioinhibitory and proangiogenic effects whereby the full-length hormone is proangiogenic and its N-terminal fragment is antiangiogenic (Table 2B ). Further work is required to elucidate which of these effects are of physiological importance in vivo. However, the potential effect of an intrinsic dynamic balance of angiogenesis residing within a single hormone is an attractive concept for regulation of various physiological processes, such as human placental vascularization (162).
E. Extracellular matrix, invasion, and metalloproteinases
The matrix metalloproteinases (MMP) are a family of zinccontaining endopeptidases that are able to degrade the extracellular matrix and allow angiogenesis and tumor invasion, with each MMP acting on a different substrate (177, 178) . MMP activity is balanced by tissue inhibitors of metalloproteinases (TIMPs) (179 -181) . MMP-2 and MMP-9 are both type IV collagenases that have been shown to be important in tumor invasion in vitro because they are able to break down basement membrane, in particular degrading collagen IV (178, 182) . Elevated levels of circulating MMP-9 have been demonstrated in patients with breast cancer (183) , and MMP-2 and/or MMP-9 release has been associated with tumor invasion and metastasis (184 -188) . Some authors have suggested that altered MMP-9 expression, in addition to MMP-11, characterizes epithelial tumors committed to malignant transformation, possibly relating to underlying genetic events that change the tumor phenotype to invasive (189) .
MMP secretion is an important early process facilitating migration of endothelial cells through both the extracellular matrix and angiogenesis (190) . In vitro studies have shown that microvascular endothelial cells do not constitutively secrete MMP-9; however, when exposed to an angiogenic stimulus (e.g., TNF-␣), MMP-9 production is up-regulated (191) . Angiogenesis can be inhibited by endogenous TIMPs (192, 193) and also by administration of synthetic MMP inhibitors (e.g., KB-R7785) (194, 195) . In addition to permissive effects on angiogenesis, MMP-9 also possesses angiostatinconverting enzyme activity, cleaving plasminogen to angiostatin, thus enhancing inhibition of angiogenesis (196) , and potentially leading to a balance of proangiogenic activity and inhibition (29) .
There are less data on the interaction between hormones and the MMPs (Table 2C ). It is interesting to note that consistent with the down-regulatory effect of glucocorticoids on VEGF and angiogenesis, a reduction in MMP-9 expression with up-regulation of the enzyme TIMP-1 in the submucosa of the airways of patients with asthma treated with glucocorticoids has been demonstrated (197) .
A potentially important role of the MMPs in degradation of IGF binding proteins (IGFBPs) may influence IGF bioavailability and therefore alter IGF activity. MMPs including MMP-1, MMP-3, and MMP-9 degrade IGFBP-2, -3, and -5, and this can be inhibited by TIMP-1 (205) (206) (207) (208) (209) . Reduced IGFBP-3 proteolysis due to TIMP-1 overexpression in a murine hepatic tumor model leads to reduced IGF-II and inhibition of liver hyperplasia (208) . MMPs therefore do not only regulate tumor invasiveness but may in addition lead to increased IGF bioactivity, which may also influence tumor growth and angiogenesis.
F. Importance of angiogenesis
The assessment and understanding of differences in angiogenesis in endocrine tumors may potentially allow accurate distinction of benign from malignant tumors (e.g., adrenal tumors and thyroid follicular neoplasms). In the pituitary gland, where it may be particularly difficult to predict subsequent tumor behavior, differences in angiogenesis may be helpful in assessing tumors more likely to recur or become aggressive and invasive. Because nonfunctioning tumors bear no useful tumor marker, it may be possible to use measurement of an angiogenic factor to determine whether complete tumor removal has been effective or whether tumor regrowth has occurred. Elucidation of angiogenesis mechanisms may help in understanding pathophysiology of hematogenous metastasis of follicular thyroid tumors and lymphatic spread of papillary tumors, or the very vascular phenotype of tumors in Von Hippel Lindau (VHL) syndrome, or why some pituitary tumors do not progress in 
III. Pituitary Tumors
Pituitary tumors are common intracranial neoplasms, with up to 10% of the population harboring an incidental tumor, although clinically relevant tumors in terms of endocrine or mass effects are less common. The majority of tumors are benign and do not metastasize, although some will become invasive, leading to destruction of bone and infiltration within the cavernous sinus or elsewhere around the pituitary fossa. The reasons for differences in tumor behavior are poorly understood, and there are currently no reliable means of predicting subsequent pituitary tumor behavior with regard to growth, local invasiveness, or recurrence. (Table 4) . Schechter (217) reported in 1972 that the parenchyma of pituitary tumors appeared less vascularized than autopsy specimens of normal tissue. Jugenburg et al. (218) used immunostaining for F8 to assess vascular density in a group of pituitary adenomas and carcinomas and showed that pituitary adenomas had lower vascular densities compared with the nontumorous pituitary.
A. Microvascular density of tumors

Comparison of pituitary tumors with normal gland
Using the endothelial markers CD31 and UEA1 in a large cohort of different pituitary adenomas and quantification of (220) . An alternative explanation may be that these relatively slow-growing tumors have low metabolic demands that do not require increased vascularization.
Although there are outstanding questions, the limited data available demonstrate that pituitary tumors are less vascular than the normal gland. However, these studies in human pituitary tumors appear to demonstrate a different pattern of angiogenesis from the animal studies performed by Weiner's group (221) , in which tumor formation in estrogen-induced prolactinomas in rats was associated with increased arteriogenesis. The net balance of proangiogenic growth factors, e.g., VEGF and FGF-2 and inhibitors of angiogenesis, will determine angiogenesis in the pituitary (both normal and tumors). Potential inhibitors are mainly speculative for the pituitary, but candidates include 16-kDa PRL and leukemia inhibitory factor (LIF) (167, 222). (Table 5 ). Jugenburg et al. (218) showed an association between MVD as a measure of angiogenesis and pituitary tumor behavior; higher vascular densities were found in the rare pituitary carcinomas compared with benign adenomas. Another study used F8 to measure vascular density in 22 pituitary adenomas and reported that the highest vascular counts were found in FSH-expressing adenomas and lowest in GHsecreting tumors (224) . Vascular density and tumor size or normal pituitary tissue were not compared.
Angiogenesis and pituitary tumor behavior
Differences in angiogenesis in different-sized tumors have been studied in prolactinomas (nine microprolactinomas and CD31, F8, UEA1, Chalkley counts PRL, Prolactinoma; GH, GH-secreting tumor; FSH, FSH immunostaining nonfunctioning pituitary adenoma; Macro, macroadenoma (Ͼ1 cm in diameter); and Micro, microadenoma (Ͻ1 cm in diameter). CD31, F8, and UEA1 represent the immunostaining techniques used to identify endothelial cells. Chalkley point, % capillary area, and electron microscopy describe techniques used to quantify labeled endothelium. 7 represents no difference in MVD between tumors after pretreatment with drug, and those where no pretreatment occurred. nine macroprolactinomas) (223) . These authors reported no difference between vascular density of the normal gland and microprolactinomas, but surprisingly that macroprolactinomas exhibited a much lower degree of vascularization. The reasons for these conflicting results may be at least partly technical and depend on the technique used to identify vasculature and the method used to quantify it.
We have shown a relationship between MVD and tumor size in prolactinomas and observed that microprolactinomas are less vascular than macroprolactinomas (Fig. 3 ). In contrast there was no difference between different-sized GHsecreting tumors (219) . This finding is consistent with the notion that microprolactinomas represent a quite different pathological and clinical entity (227, 228) from macroprolactinomas, whereas different-sized GH-secreting tumors are part of the same disease spectrum. Additionally, MVD and serum PRL concentrations correlated positively, although no relationship with ACTH or GH secretion in ACTH-secreting or GH-secreting tumors was found (225) . Bromocriptine or metyrapone treatment of patients with prolactinomas or Cushing's disease, respectively, did not alter MVD of tumors compared with the MVD in tumors removed from patients who did not receive preoperative drug treatment. A recent study, however, has demonstrated that dopamine, signaling through endothelial cell D2 receptors, inhibits VEGF action, possibly by endocytosis of VEGFR-2 (229). Bromocriptine and quinpirole (D2 agonists) inhibit angiogenesis in a mouse ovarian tumor model (229) . It might therefore be expected that bromocriptine or cabergoline should lead to angiogenesis inhibition in pituitary tumors. Two explanations for the difference between the animal model and human pituitary tumors are firstly that the typical patient undergoing surgery for a prolactinoma is resistant to, or intolerant of, the drug, and therefore a true comparison may not be valid. Alternatively, VEGF is secondary in importance to other factors (e.g., FGF-2) in stimulation of angiogenesis in pituitary tumors. In vitro studies of D2 agonists and prolactinomas will be helpful.
In terms of tumor behavior, MVD did not predict regrowth of nonfunctioning adenomas, suggesting that factors other than angiogenesis determine nonfunctioning tumor (NFA) recurrence (e.g., surgical technique). In contrast, MVD was related to tumor invasiveness and malignancy (218, 225) . Higher vascular densities were found in those tumors showing local invasion of the cavernous sinus and bone and in rare pituitary cancers consistent with a relationship between aggressive pituitary tumor behavior and angiogenesis. Using a malignant pituitary tumor cell line (MGH3), PTHrP has been shown to increase new blood vessel formation in cell diffusion chambers implanted into rat sc tissue (136). Using in vitro techniques with bovine aortic endothelial cells in collagen gel and 8-bromo-cAMP, this study further demonstrated that the proangiogenic effect of PTHrP is unlikely to be directly due to increased endothelial cell proliferation or migration, but rather to capillary tube formation possibly via a cAMP pathway. Although PTHrP expression has only been shown in a metastatic pituitary GH-secreting tumor (230) , it is known that PTHrP is produced by other malignant tumor types, and its role as a promoter of angiogenesis may therefore have more universal importance. (Table 6 ). Assessment of cell proliferation using Ki-67 (a measurement of the proportion of cells within the cell cycle), showed no association between assessment of angiogenesis using MVD and cell proliferation (226) , consistent with other tumor types, e.g., breast and colorectal cancer in which intratumoral MVD and Ki-67 labeling index were not related (86, 231, 232). A positive relationship was, however, observed between expression of the antiapoptotic protein bcl-2 and increasing MVD (226) , suggesting that there may be an association between angiogenesis and apoptosis; a switch to an angiogenic phenotype and bcl-2 expression (preventing programmed cell death) may be early events in pituitary tumor pathogenesis. VEGF has been shown not only to stimulate endothelial cell proliferation but also to prolong endothelial cell survival by inducing expression of bcl-2 (233). Thus, angiogenesis appears to be related to the ability of pituitary tumor cells to survive, rather than their proliferative capacity.
Relationship with cell proliferation
B. Pituitary vasculature
The anterior pituitary gland is unusual in receiving a dual blood supply, unlike the majority of other tissues in which angiogenesis has been studied. The main vascular source is the hypothalamo-hypophyseal portal system carrying blood with releasing and inhibitory factors from the hypothalamus. There is also a direct arterial blood supply derived from the systemic vasculature (Fig. 4) . The source of the blood supply to tumors is currently unknown, raising further questions regarding the source of new tumor vessel formation and potential for alteration in hormonal regulatory feedback pathways.
The anatomy of the blood supply to the pituitary gland was first described by Popa and Fielding (234, 235) in 1930 when they demonstrated the portal arrangement of the vasculature to the anterior pituitary gland. Harris and Jacobsohn (236) later showed that the portal blood supply played an important role in the connection between the hypothalamus and anterior gland.
A number of controversies remain regarding the normal vascular supply to the anterior gland. Whether the blood supply to the anterior pituitary gland arises exclusively from the portal system is not entirely clear. Some authors also describe the presence of a loral artery, which arises from the anterior hypophyseal artery and enters the superior surface of the anterior lobe; in addition, they suggest that capsular arteries may also provide an arterial supply (237) . Others disagree on the presence of a direct systemic source to the anterior gland (238) . It is likely that the capsular arteries may supply a small number of cells in the anterior gland, but the predominant vascular supply to the normal adenohypophysis is portal in origin.
There are few studies assessing the source of the vascular supply to human pituitary adenomas. A neuroradiological study performed when angiography and pneumoencephalography were the usual imaging methods performed in the diagnosis of pituitary tumors demonstrated that at least a portion of the blood supply to tumors arose from the systemic vasculature. This was derived from branches of the internal carotid artery, most commonly the capsular and inferior hypophyseal arteries (239) . A more recent neuroradiological study has extended these findings by using dynamic magnetic resonance imaging (240) and showed that enhancement of the posterior lobe could be demonstrated before the anterior lobe, as would be expected, but that macroadenoma enhancement also occurred before anterior lobe enhancement, suggesting that pituitary adenomas received a direct blood supply similar to the posterior lobe.
Intrasellar pressure in patients undergoing transsphenoidal surgery for pituitary adenoma is elevated, with a mean pressure of 25 mm Hg, compared with normal pressure of 10 mm Hg (241) . This elevated pressure could obstruct the portal venous supply and therefore reduce the delivery of the normal controlling hypothalamic factors. Hyperprolactinemia observed in association with stalk compression syndrome could be related to compression of the portal blood supply. The lack of infarction or ischemia seen in the majority of tumors despite increased intrasellar pressure argues for an additional source of circulating blood. It is suggested that only a systemic arterial supply would allow maintained perfusion to the pituitary gland in this situation. The waveform of intrasellar pressure is pulsatile in two thirds of patients with tumors and in synchrony with the arterial waveform (241) . The pressure was higher than venous pressures and may therefore be further evidence for a direct systemic arterial supply to pituitary tumors.
Two morphological studies also provide evidence for a direct arterial blood supply to pituitary adenomas (242, 243) . Examination of the pituitary gland at autopsy of subjects with no known endocrine disorders demonstrated the presence of a microadenoma in 27%, and cannulation of the internal carotid artery and injection of dye demonstrated that two thirds of microadenomas had a direct extraportal blood supply (242) . An electron microscopic examination of the vasculature within 16 prolactinomas showed that 13 contained arteries, but in contrast morphological evidence for arterial formation was not found in eight normal control pituitary glands (243) . Interestingly, tumors with no arterial supply were described as small, although measurements were not provided.
These studies lend support to the notion that pituitary adenomas, in contrast to the normal anterior pituitary gland, receive a direct systemic arterial blood supply. In the liver (another organ with both a portal and direct arterial blood supply), the majority of metastases are supplied directly by the hepatic artery rather than the hepatic portal vein (244) . A potential explanation for the relatively low vascular density of pituitary adenomas is that there has indeed been increased angiogenesis, but this has led to in-growth of blood vessels from the systemic circulation and the exclusion of the hypothalamic controlling factors found in the portal circulation.
Studies of the structure of pituitary tumor vasculature show the majority to be thin-walled fenestrated capillaries and give little clue as to the source of the vessel (systemic or portal). Some studies have suggested that ultrastructural changes (endothelial cell swelling and blebbing) seen in capillaries from pituitary tumor specimens may be due to tumor growth leading to compression of the long portal veins and ischemia (217) . These studies have also suggested that tumor specimens were less well vascularized than the normal anterior pituitary gland derived from autopsy specimens and that the number of fenestrations may be reduced or even absent in pituitary tumors (217, 245) . Altered parenchymatous basement membrane has been demonstrated in pituitary adenomas in which complete absence or fragmentation has been reported (246) . This may be due to reduced synthesis or breakdown of the basement membrane by the tumor.
C. Angiogenesis in animal models of pituitary tumors
Studies of estrogen-induced lactotroph hyperplasia and tumor formation in rats with different susceptibility to estradiol have led to useful insights into the blood supply of pituitary tumors. Microspheres injected into the left side of the rat heart were trapped in the first capillary plexus they reached and did not reach the anterior pituitary gland (247) . In contrast, rats with estradiol-induced lactotroph hyperplasia and PRL-secreting tumors exhibited numerous microspheres in the anterior pituitary gland, suggesting development of a direct arterial blood supply and confirmed as branches of vessels coursing through the dura (248) . A direct arterial supply would be expected to potentiate lactotroph hyperplasia because the dopamine content of this source would be relatively low. Administration of bromocriptine reduced the effect of estradiol on both pituitary weight and serum PRL, as well as decreasing arteriogenesis (248) . It was unclear, however, whether bromocriptine alters vasculature once formed. Hypotheses raised in this paper include the possibility that estradiol may induce vascular proliferation directly or via induction of an angiogenic factor such as FGF, or that estradiol suppressed the production of a substance that normally inhibits angiogenesis. Estrogen treatment also led to altered vascular ultrastructure coincident with tumorigenesis in estrogen-sensitive rats (249) , in keeping with Schechter's observation (217) in 1972 that tumors appeared less well-vascularized than the normal pituitary gland and blood flow per unit weight to pituitary tumors induced in rats by prolonged estrogen treatment is reduced (250) .
D. Angiogenic factors
The angiogenic factors VEGF and FGF-2 were first isolated in the folliculostellate cells (FSC) of the pituitary gland.
1. FSC. FSC were first described in the pituitary gland by Rinehart and Farquhar (251) and are characterized by their shape and long slender cytoplasmic processes. They can be identified using immunohistochemistry for S100 (252) , although not all FSC immunostain positively for S100 (253) . Although they compose follicles early in fetal development, they become stellate and form a reticular network throughout the adenohypophysis, connected to each other and adjacent endocrine cells by junctional complexes. It has been suggested that they play a role in compartmentalization of the anterior pituitary gland and that follicles are interconnected via FSC (254) . Apart from a paracrine role, the presence of a Golgi apparatus and endoplasmic reticulum as well as phagocytic vesicles and lysosomal organelles is consistent with an active metabolic as well as a catabolic role (254 -257) , and the production of cytokines such as IL-6 production is in keeping with a suggested homology with dendritic cells (253) . Ferrara et al. (258) studied follicular cell function after enzymatic dispersal of bovine anterior pituitary gland and in vitro culture. They demonstrated production of FGF-2 (259), a new growth factor-VEGF (260) , and a possible angioinhibitory cytokine-LIF (222) from these cultures. The presence of FSC in pituitary adenomas has been investigated by different groups with conflicting results. We and others have shown that 35% (14 of 40) to 43% (61 of 93) of pituitary tumors contained S100-positive FSC (261, 262) . In contrast, others find that FSC are rarely present in pituitary adenomas (263, 264) . An unexplained finding is that GH-secreting tumors were most likely to contain FSC (261, 265) . A universal finding is that FSC are more common in the normal anterior pituitary gland than in pituitary adenomas.
Animal models of pituitary tumors have demonstrated that FSC become activated during estrogen-induced prolactinoma formation in rats, with the appearance of cytoplasmic phagosomes and evidence of parenchymatous basement membrane degradation (257) . This may be an important step in tumor progression, perhaps allowing angiogenesis and therefore tumor growth. The new technique of laser capture microdissection, which allows single cell isolation, will allow a clearer role for the FSC to be elucidated (266). (Table 7A ). VEGF was first described in pituitary gland extracts (260) . In animals, VEGF expression has been shown in rat, ovine, and mouse pituitary. Overexpression of VEGF in Fischer 344 rat pituitary glands and the GH3 cells has been demonstrated during estrogen-induced tumor angiogenesis (267, 273) . These studies also demonstrated upregulation of VEGFR-2 in estrogen-induced rat pituitary tumors and the presence of VEGFR-1 in sheep pituitary gland endothelial cells (267, 269) . VEGF expression has also been shown by immunohistochemistry in a small selection of human pituitary adenomas in which it was diffusely distributed in tumor cells (226) . Studies of larger cohorts of human pituitary adenomas using immunohistochemistry and ISH have shown higher VEGF expression in the normal gland compared with adenomas ( Fig. 5) (271, 272) . These studies also showed a relationship with tumor behavior (higher in carcinomas and macroprolactinomas) and measures of angiogenesis. In contrast, a study using autopsy-derived pituitary as a normal control and RT-PCR showed higher VEGF expression in adenomas (275) . The differing results between these studies may be due to the use of different normal controls. Surrounding nontumorous pituitary tissue may theoretically be subject to subtle changes due to the presence of a tumor, whereas degradation and time to fixation may lead to loss of detectable cytokines in autopsy tissue.
VEGF
Colocalization of VEGF and S100 was shown in some cells in the ovine and human pituitary gland, suggesting that some VEGF-secreting cells are folliculostellate (262, 269) . However, not all VEGF-secreting cells were identified as FSC, and not all FSC secreted VEGF. Immunoelectronmicroscopy has shown VEGF to be present in secretory granules, Golgi apparatus, and rough endoplasmic reticulum of GH3 cells (273) . VEGF is present in the epithelial cells of the normal pituitary and colocalizes with anterior pituitary hormones (270) .
Regulation of VEGF expression has been studied in different models (Table 7B) . Estradiol, IL-6, and pituitary adenylate cyclase activating peptide (PACAP) have all been shown to increase VEGF expression, whereas dexamethasone (as in other cell types; Table 2A ) inhibits VEGF. We have shown that hypoxia is an important stimulus to VEGF expression in cultured human pituitary adenoma cells (Fig. 6) . Further studies are required to investigate whether this occurs via the HIF-1 signaling pathway.
FGF.
The FSC have been shown to be a major source of FGF-2 (259), although human pituitary adenomas also contain and release FGF-2 (278 -282). FGF-2 does not appear to stimulate cell proliferation in the pituitary (283) but may lead to lactotrope differentiation (284) . The finding of lower FGF-2 concentrations in pituitary adenomas, as compared with normal anterior pituitary, has led some to suggest that a reduction in FGF-2 may lead to increased tumor growth (278) . Others, however, suggest that FGF may play an important role in tumor progression, perhaps by favoring angiogenesis (248, 279) . This is further supported by work with the recently described pituitary tumor-transforming gene (PTTG) (285-288) (see Section III.D.5). Human PTTG-transfected fibroblasts demonstrate elevation of FGF-2 in conditioned medium and increased angiogenesis in vitro (HUVEC) and in vivo (CAM assay).
LIF.
LIF has been detected in conditioned medium from bovine pituitary follicular cells in culture (222) . Because LIF inhibited aortic endothelial but not adrenal capillary cell proliferation, it has been suggested that LIF may inhibit arteriogenesis in the pituitary gland, ensuring that the majority of the blood supply is capillary in origin, containing the regulatory hypophyseal factors (222) . LIF has been shown to be present in normal adult pituitary tissue as well as human pituitary adenomas (289) and Rathke's cleft cysts (290) .
E. Genes and regulation of angiogenesis
PTTG was cloned from the rat pituitary cell line GH4 (285) . Overexpression of rat PTTG in NIH-3T3 fibroblasts induced cellular transformation in vitro and in vivo in nude mice (285) . Human PTTG is expressed in most pituitary adenomas at higher levels than in the normal gland, and human PTTG protein is demonstrable in adenoma cell cytoplasm (286) . The exact role of PTTG in pituitary tumor development is as yet unclear. Recently, PTTG has been identified as a mammalian securin homolog and shown to inhibit chromatid separation, interfering with mitosis and potentially inducing genetic instability (291) . PTTG expression and phosphorylation are related to mitosis, suggesting that PTTG may play a role in cell proliferation (292) . Experiments using the estrogen-induced rat prolactinoma model showed that estradiol also induced PTTG expression, followed within 24 h by increased FGF-2 and VEGF expression, associated with new pituitary blood vessel expression (281) . Concordant expression of PTTG and FGF-2 was shown in human pituitary adenomas. Thus, PTTG overexpression may be an important mechanism of estrogen-induced tumorigenesis and angiogenesis. Administration of FGF-2 antibodies to conditioned medium derived from human PTTGtransfected 3T3 cells led to abrogation of angiogenesis in vitro and in vivo. The mechanism whereby PTTG is able to induce FGF-2 is currently unknown. FGF-2 has also been shown to induce cyclin D3 expression in rat pituitary (293) . This may therefore provide a mechanism for an increase in cell proliferation associated with angiogenesis because cyclin D3 plays an important role in cell cycle control.
F. Matrix metalloproteinases
Tumor invasion of surrounding tissues is characteristic of more aggressive and often malignant tumor behavior. A previous small study demonstrated that three invasive pituitary adenomas showed high MMP-9 activity in contrast to four noninvasive tumors (294) . More recently, an in vitro study of cultured pituitary tumors has shown secretion of another MMP type IV collagenase-MMP-2 from pituitary tumors (295) . In addition, this study showed the presence of pro-MMP-9 in two thirds of conditioned medium from cultured tumors.
Assessment of MMP-2 expression using immunohistochemistry in a cohort of human pituitary tumors showed no relationship with pituitary tumor behavior (our unpublished observations). In contrast, however, MMP-9 expression was related to macroprolactinoma invasiveness and nonfunctioning tumor regrowth (296) , suggesting that MMP-9 expression is related to aggressive tumor behavior. MMP-9 expression, as expected, was associated with increased angiogenesis, but the mechanism of MMP-9 regulation in pituitary tumors is unknown. Several potential upstream promoters (e.g., cAMP response element binding protein, somatostatin, cyclin D1, FGF-2), may activate MMP-9 expression (297-300).
G. Therapeutic application of angiogenesis inhibitors
There are few descriptions of the therapeutic use of inhibitors of angiogenesis in endocrine tumors. There have been some preliminary data in the Fischer 344 rat estrogeninduced prolactinoma model, suggesting that a synthetic inhibitor of angiogenesis may have a beneficial therapeutic effect (301, 302) . These studies both investigated the effects of the fumagillin analog TNP-470 and demonstrated a reduction in lactotroph proliferation and neovascularization. This is further evidence of the potential importance of angiogenesis in pituitary tumor behavior. Somatostatin analogs have been demonstrated in vitro to possess angioinhibitory activity (157-160), although it is unknown whether this is clinically relevant in, for example, acromegaly where these analogs are frequently used to control excess GH secretion.
In contrast to other tumor types, pituitary tumors are less vascular than the normal pituitary gland. Whether this is due to endogenous inhibitors of angiogenesis controlling the angiogenic switch, the relatively low growth rate of these tumors, or an ingrowth of a vascular supply from the systemic circulation is not yet known. There is clearly a relationship between tumor behavior and MVD in some tumor types. In the future, it will be important to explore whether these differences can be used to identify tumors with a more aggressive prognosis or to use serum or urinary markers to monitor tumor progression and also assess the role of newly developed antiangiogenesis therapies in treatment.
IV. Adrenal Tumors
Both the normal adrenal gland and adrenal tumors are vascular structures. There is a complex arrangement between the different zones of the cortex and medulla whereby different hormones are synthesized in different areas and may play a role in the metabolism of other hormones, for example the effect of glucocorticoids on catecholamine metabolism. Similar to the pituitary gland, incidental adrenal cortical tumors are commonly encountered, but malignant tumors are found more commonly in the adrenal than the pituitary gland, and the differentiation of benign and malignant can be difficult when simply observing a histological specimen. Adrenal medullary tumors are associated with various familial syndromes, e.g., multiple endocrine neoplasia (MEN) 2, neurofibromatosis type 1 (NF-1), and VHL syndrome. Differences in angiogenesis and the balance of angiogenic growth factors and inhibitors may play a role in determining the observed variations in tumor behavior. A better understanding of the underlying mechanisms may help with understanding and predicting tumor biology in the adrenal gland.
A. Microvascular density of tumors
No differences in vascular density between the normal adrenal cortex, adrenal adenomas, and carcinomas were observed using CD34 as the endothelial marker (303) ( Table 8) . However, MVD was related to tumor behavior in pheochromocytomas, showing that invasive tumors had a significantly higher number of blood vessels than noninvasive tumors (304) . Although it is likely that more aggressive tumors do have higher levels of angiogenesis, there was also a difference in tumor size between the two groups, but the relationship between angiogenesis and size was not assessed.
B. Angiogenic factors
VEGF expression has been demonstrated by immunohistochemistry in the normal adrenal medulla of the rat adrenal gland (305) . VEGF is present at an early stage in fetal adrenal cortical development (16 -20 wk) and is positively regulated by ACTH (116). Expression of the proangiogenic factors VEGF and platelet-derived endothelial cell growth factor have been demonstrated by immunohistochemistry, Western blot, and ELISA in a series of surgically removed paragangliomas, but there are no data regarding a relationship with tumor behavior (306) . Serum VEGF is elevated in patients with adrenal tumors undergoing surgery (307) . One month after surgery, there was a significant reduction in serum VEGF levels in patients with both cortical cancers and benign adrenocortical adenomas. However, whether serum VEGF provides a marker of long-term disease control or recurrence is not known.
Cultured bovine adrenal cortex cells express the FGF-2 gene and release FGF-2, which stimulates proliferation of adrenal cortical cells (308 -310) . The presence of FGF-2 and type IV collagenase (an enzyme that is able to break down the extracellular matrix) has been demonstrated in pheochromocytomas (311)
C. Matrix metalloproteinases
ISH has shown the presence of gelatinase A (MMP-2) in stromal tissue of neoplastic adrenal tumors (313) . MMP-2 was undetected from benign tissue, providing preliminary information to suggest perhaps that MMP-2 may play a role in malignant adrenal tumor behavior. Membrane type 1 MMP (MT1-MMP), which activates gelatinase A, was present in both stromal and neoplastic tissue. More data on these, other MMPs, and their regulation are required.
D. Genes and regulation of angiogenesis
Adrenomedullary tumors and VHL syndrome.
VHL is an inherited cancer syndrome caused by a germline mutation of the VHL tumor suppressor gene, followed by functional loss of the remaining wild-type allele. It is characterized by extensively vascularized tumors including renal cell carcinoma and hemangioblastoma. It has recently been demonstrated that renal carcinomas lacking wild-type VHL protein express mRNA for VEGF under normal as well as hypoxic conditions (314) (Fig. 7) . Reintroduction of wild-type VHL inhibited production of VEGF mRNA under normoxic conditions (315) . It was therefore likely that VHL protein regulates VEGF expression and that VHL inactivation leads to loss of VEGF suppression (316) . The VHL/VEGF mechanism has recently been further elucidated by the demonstration that the VHL protein has a critical role in degrading HIF-1␣, thus blocking binding to the HREs of the hypoxia-responsive genes (317) . VHL interacts with other cellular proteins, forming a complex with sequence and structural similarity to the SCF class of ubiquitin ligases (318) . The VHL protein acts as an E3 ubiquitin ligase specific for HIF␣-subunits, and this leads directly to oxygen-dependent ubiquination and degradation of HIF in the proteasome (319) . The angiogenic phenotype of VHL tumors may therefore be due to constitutive HIF-1 activity. The VHL gene also plays a role in regulation of PAI-1, with lower plasminogen-activator mRNA and protein levels and higher PAI-1 levels in renal cell carcinoma cells expressing the mutant VHL gene (320) . This would lead to a reduction in plasmin-mediated proteolysis of the extracellular matrix and therefore slower tumor growth and later development of metastases. Unlike renal cell carcinoma in which the VHL gene is inactivated in 75% of cases, the majority of sporadic pheochromocytomas are not associated with mutations in the VHL gene (321) . However, it is not known whether differences in angiogenesis or VEGF expression occur in sporadic and VHL-associated pheochromocytomas. HIF2 (EPAS1) is another hypoxia-inducible transcription factor with almost 50% identity to HIF1␣ (322) . Mice engineered to be deficient in HIF2 were shown to have low catecholamine concentrations and to develop heart failure (323). Administration of a catecholamine precursor d,lthreo-3,4-dihydroxyphenylserine to the mother protected from midgestation death, suggesting that HIF2 may play a role in catecholamine synthesis (323) . Although the data are more preliminary, HIF2 may also play an important role in adrenal medullary function, and possibly tumor formation.
NF-1.
Pheochromocytomas also occur in patients with the inherited syndrome NF-1. Another candidate for an association between a genetic abnormality and angiogenesis is the proangiogenic factor midkine, and aberrant expression of midkine has been shown in the skin of patients with NF-1, but not in normal controls (324) . Midkine-containing culture medium leads to increased endothelial and neurofibromaderived cell proliferation, suggesting that midkine may be associated with NF-1.
Adrenocortical tumors.
Genetic abnormalities found in adrenocortical tumors include overexpression of the IGF-II gene in malignant tumors, leading to a mitogenic effect via the IGF-I receptor (325, 326) . In hepatocellular carcinoma, IGF-II is also highly expressed, and it has recently been shown that hypoxia is a major stimulus to IGF-II expression, leading to increased VEGF mRNA and protein expression (130). IGF-II also led to increased angiogenesis, as demonstrated on the chick CAM assay (327) . Thus, a possible link between known genetic abnormalities in adrenocortical carcinomas and angiogenesis is overexpression of IGF-II leading to increased angiogenesis. This concept, however, is yet to be explored within adrenal tumors.
E. Therapeutic application of angiogenesis inhibitors
There are no data on the effects of inhibitors of angiogenesis in adrenal tumors. However, early studies have investigated the possibility of therapy for VHL. To prevent further progression of VHL, a preliminary study investigating the effect of blockade of VEGF signaling is in progress (328) . This involves the use of a VEGF tyrosine kinase receptor inhibitor (SU 5416), and although early results suggest it is well tolerated, there is no published outcome information, and no patients with pheochromocytomas have been studied. An animal study, however, has investigated the effect of another antiangiogenic agent, linomide, on VHL paraganglioma growth in nude mice (329) . Reduction in tumor size, tumor vascularization, and VEGF mRNA was observed. These are preliminary reports, but they demonstrate that antiangiogenic therapy may be a potential adjunct in patients with VHL and phaeochromocytoma.
Thus, although there has been progress on the link between angiogenesis, tumor phenotype, and genetic abnormalities in VHL, there are few data on MVD or angiogenic factors in nonfamilial adrenocortical or medullary tumors. It would be important if an assessment of, for example, MVD allowed differentiation of benign from malignant phaeochromocytoma or if noninvasive assessment of vascularization predicted true incidental tumor compared with a biologically important tumor. 
V. Thyroid Tumors
Angiogenesis plays an important role in goiter development with endothelial cell proliferation occurring before increased proliferation of the thyroid follicular cells (330) . Conditioned medium derived from cultured rat and porcine thyroid follicular cells increases endothelial growth and migration, suggesting a paracrine mechanism for angiogenesis control in the thyroid by endogenous angiogenic factors (331) . Similarly, increases in both serum VEGF and the intrathyroidal vascular area have been shown in patients with Graves' disease and Hashimoto's thyroiditis (332) .
A. Microvascular density of tumors
Thyroid tumors are more vascular than the normal thyroid gland. Assessment of angiogenesis using F8 labeling and quantification of MVD at hot spots in 128 papillary thyroid cancers demonstrated a threefold increase in tumor vascularity as compared with normal thyroid tissue (333) ( Table 9 ).
Similar to other tissues, MVD is increased in malignant tumors when compared with benign tumors (335) , but some studies have rather surprisingly shown that reduced MVD is associated with poor differentiation (333, 336) , a worse prognosis, and reduced survival (333) . In contrast, two other studies demonstrate increased risk of recurrence and shorter disease-free survival in the more vascular papillary thyroid tumors (337, 338) . Higher MVD is associated with a worse outcome in medullary thyroid carcinoma (339). These studies have used different techniques to quantify MVD using different endothelial markers-F8, CD31, and CD34; some have deliberately assessed vessel counts at hot spots, whereas others did not. This heterogeneity of methodology may explain some of the disparate results between studies. It is, however, surprising that some studies, perhaps rather counterintuitively and in contrast to results derived from other tissues, demonstrate that higher vascular density is associated with a more differentiated grade or better prognosis than tumors exhibiting lower vascular density.
The finding of a higher rate of vascularization in microinvasive follicular carcinomas, particularly adjacent to or penetrating the capsule, is consistent with the hypothesis that vascularity may play a role in tumor spread in follicular thyroid tumors (335) . This is important because follicular tumors tend to spread via the blood stream, whereas papillary thyroid tumor spread occurs via the lymphatic system.
B. Angiogenic factors
1. VEGF. VEGF is present in epithelial cells of normal thyroid gland, goiter, Graves' disease, thyroiditis, and thyroid tumors (Table 10 ). Increased VEGF is demonstrable in thyroid tumors when compared with normal gland or benign tumors, although interestingly, papillary microcarcinoma does not show increased VEGF expression when compared with normal thyroid gland (344) .
VEGF is not a marker of malignancy in the thyroid gland and is increased in goiter (119, 342), in enlarging and recurrent thyroid nodules, with no difference between VEGF concentrations in patients with goiter or benign adenomas (120). The biological relevance of this finding is unclear. VEGF and its receptors have also been demonstrated in thyroid gland specimens resected from patients with Graves' disease (119). TSH and Graves' IgG increase VEGF mRNA levels in human thyroid follicles in vitro (119, 120) and increase constitutive VEGF secretion by thyroid cell lines in culture (121). Studies of thiouracil-induced hypothyroidism demonstrated that el- (339) evated TSH leads to increased VEGF, which subsequently leads to VEGFR expression (120). Serum VEGF is elevated in patients with untreated Graves' disease and Hashimoto's thyroiditis (332), correlating circulating VEGF levels and intrathyroidal vascular area assessed by color flow Doppler ultrasonography. VEGF-C and VEGFR-3 have also been demonstrated in human thyroid goiter and autoimmune disease (345) . VEGF expression appears to be related to aspects of thyroid tumor behavior (Table 11 ). Higher VEGF expression is present in metastatic thyroid cancer when compared with nonmetastatic disease (341) . Lymph node metastases of thyroid tumors showed increased VEGF with respect to the primary tumor (344) . An attempt at quantification of VEGF expression using the percentage of labeled thyrocytes and intensity of immunostaining in papillary thyroid cancer demonstrated higher VEGF expression in metastatic compared with nonmetastatic cancers (348) . The authors suggest this technique as a method for distinguishing those thyroid tumors more likely to metastasize. Differences in VEGF expression alter tumorigenic potential in thyroid cancer cell lines (347) . VEGF overexpression in poorly tumorigenic cells led to the development of well-vascularized tumors, whereas transfection of an antisense construct to VEGF into an anaplastic cell line led to smaller tumors and poor vascularization (347) . Higher VEGF expression correlates with tumor size in adults (344) and children (349) .
The clear relationship between VEGF expression and tumor behavior is in contrast to the rather confusing data on the significance of MVD in thyroid tumors. It would be important to reassess this using a measurement of new blood vessel development using, e.g., Tie-2 to determine whether this results in a more robust relationship with outcome. The correlation between VEGF expression and MVD would also be relevant because the relationship may be tighter with new vessel formation rather than total vasculature. In both papillary and follicular thyroid cancer, increasing VEGF expression parallels increases in cell proliferation assessed using the Ki-67 labeling index, suggesting that areas of increased cell division increase VEGF secretion, allowing increased angiogenesis (341) . This is in contrast to the observation in pituitary adenomas in which no relationship between cell proliferation and MVD (226) was found and also differs from findings in breast and colorectal cancer (86, 231) . This may be related to differences in the respective metabolic requirements of the tissue.
Tumor expression of both VEGF-C and -D promotes lymphatic vessel formation and metastasis to lymph nodes in models of epithelial tumors in immunodeficient mice (45, 46). Expression of soluble VEGFR-3 in a transgenic mouse model led to regression of embryonic lymphatic vessels, suggesting a possible therapeutic approach to inhibit tumor lymphangiogenesis and tumor spread (47). There are some data regarding VEGF-C in thyroid tumors, which may be important because papillary tumors typically spread via the lymphatic system (Fig. 8) . A comparison of VEGF-C expression (346) . Tumors spreading via lymphatics were shown to express increased VEGF-C, whereas those that spread via the bloodstream showed a fall in TSP (an angioinhibitory factor) (344) . VEGFR-3, the VEGF-C receptor, has also been demonstrated using immunohistochemistry in thyroid tumors and has been shown to be up-regulated in some papillary thyroid tumors and their lymph node metastases, consistent with its role in lymphatic proliferation (344) . The VEGF receptor VEGFR-1 has been demonstrated in endothelial cells of normal thyroid tissue as well as endothelial cells from papillary and follicular thyroid cancer (341) . Interestingly, however, VEGFR-1 mRNA is expressed in rat thyroid epithelial cells as assessed by RT-PCR (342), suggesting a possible autocrine/paracrine mechanism of VEGF on the thyroid follicular cells themselves. The different results in these two studies may reflect the different techniques used and different tissues investigated.
There are preliminary data linking Trk B receptor with angiogenesis and tumor progression in medullary thyroid tumors. The Trk family is comprised of receptor tyrosine kinases (like RET) that bind neurotrophins and promote survival and growth of neural crest-derived cells. In medullary thyroid cancer, reduction in neurotrophin receptor TrkB expression and increase in TrkC are found in the later stages of tumor progression (350) . In a cell culture model, TrkB expression led to reduced VEGF concentrations and reduced tumorigenicity, suggesting that TrkB may inhibit medullary thyroid carcinoma angiogenesis and tumor growth, with reduced expression associated with tumor progression altering the balance of malignancy toward a more angiogenic and potentially metastatic phenotype.
Other angiogenic factors.
Another proangiogenic factor, FGF-2, and its receptor, FGF-R1, are expressed as assessed by immunohistochemistry in follicular cells from papillary, follicular, and anaplastic thyroid carcinomas, suggesting a paracrine mechanism of angiogenesis and cell proliferation (351, 352) . This had previously been suspected after studies in the rat FRTL-5 thyroid cell line, which showed that both FGF-2 and a high-affinity receptor (flg) localized and were synthesized in follicular cells (353) . Additionally, exogenous and endogenous FGF-2 was mitogenic for follicular cells. Increased extracellular FGF-2 has been shown in Graves' disease and papillary thyroid cancer, as compared with normal thyroid tissue (354) . Follicular cell FGF-2 and TGF-␤1 immunoreactivity increase during increased angiogenesis associated with goiter progression in a rat model, whereas expression of the angioinhibitory factor TSP1 fell (355). Others demonstrated increased number and intensity of follicular cells immunostaining for FGF-1 and FGF-2 in multinodular goiter, further suggesting that these growth factors are important in the development of thyroid hyperplasia (356).
Although FGF-2 has direct angiogenic effects in other tissues and is clearly increased in thyroid inflammation, goiter, and carcinoma, all of which have been associated with increased angiogenesis, there are no published studies demonstrating a direct or indirect role of FGF-2 on thyroid angiogenesis.
Angiopoietin 2 has been demonstrated in thyroid tumors, with a marked increase in mRNA correlated with tumor size (344) . Interestingly, this study showed no increase in Ang-1. Up-regulation of Tie2/Tek receptor mRNA has been shown in some of the papillary thyroid cancers and in the majority of lymph node metastases (344) . This study also showed a reduction in the angioinhibitory factor TSP in aggressive thyroid tumors. Although no differences were noted between benign adenomas and papillary microcarcinoma, down-regulation of TSP mRNA in papillary thyroid tumors was particularly associated with lymph node metastases. Follicular carcinomas showed further reduction in TSP expression, as did medullary thyroid tumors, with further down-regulation demonstrable in their metastases.
HGF is the ligand for the tyrosine kinase receptor product of the c-met protooncogene and may play a role in papillary thyroid tumor angiogenesis and, in particular, in vascular invasion. HGF is increased with thyroid cancer invasiveness in vitro using a matrigel-coated nucleopore filter (357). In human keratinocytes, HGF also increases VEGF expression and up-regulates VEGFR-1 (358). Met mRNA and protein overexpression has been demonstrated in thyroid cancer cell lines (359). These studies showed that the cell lines responded to HGF, leading to increased invasiveness. Papillary carcinoma, but not anaplastic or follicular thyroid cancer or normal thyroid gland, overexpresses both HGF and c-met (360 -363). Loss of heterozygosity (LOH) for HGF and c-met occurs in follicular and anaplastic cancer, but not papillary cancer at the loci for these proteins-7q21 and 7q31, respectively (362). It is also of potential diagnostic use in differentiation of follicular from papillary phenotype. Although some work in human thyroid tissue has not shown a correlation between c-met expression and papillary thyroid cancer behavior (364), others have shown that the extent of MET expression in papillary thyroid cancer predicts both vascular invasion and the likelihood of distant metastases (360). Activation of ras and ret oncogenes, both known to play a role in thyroid tumorigenesis, leads to overexpression of c-met, which in turn increases thyroid epithelial cell sensitivity to paracrine HGF (365). This may, in part, explain the mechanism of proliferative advantage caused by these oncogenes.
Thus, from the data available, the balance of angiogenesis in the thyroid appears to involve increases in VEGF and its receptors in addition to angiopoietin and Tie2/Tek, allowing increased tumor size and possibly metastasis. Other growth factors including FGF-2 may play a permissive role in increased angiogenesis during tumor growth and progression.
Reduction in TSP may then allow distant metastasis to occur, and VEGF-C and its receptor may play a role in lymphatic spread in papillary tumors. Expression of HGF and its receptor demonstrate a potential link between genetic abnormalities in tumors and differences in vascular invasion and tumor behavior.
C. Matrix metalloproteinases
The experimental data on the MMP family in thyroid tumors suggest that the type IV collagenase, MMP-2, may be the most important member of the family in determining thyroid tumor invasiveness (Table 12 ). Although the MMPs are expressed mainly in thyroid carcinomas, they may also be expressed in nonneoplastic tissue, most consistently in areas of thyroid inflammation.
Work Immunohistochemistry demonstrated the presence of MMP-2 in papillary and follicular thyroid carcinomas as well as lower expression in inflammatory nonneoplastic thyroid tissue (369). An investigation using sandwich enzyme immunoassays of MMP expression in human invasive papillary thyroid carcinoma demonstrated that only MMP-2 production is enhanced when compared with adenomas and normal 1 MT1-MMP in carcinoma, correlated with 1 active MMP-2 (370) 1 MMP-2 associated with lymph node metastasis (369) MMP-2 present in thyroid fibroblasts, in contrast to MMP-9, which was present in thyrocytes (371)
1 MT1-MMP associated with distant metastasis (371) IL-1 and TNF␣, no effect. MMP-9
Thyroid papillary carcinoma and cell lines (C643, HTH 74, SW74, and 8505C) (370, 371) 
thyroid gland (370). Activation of MMP-2 from pro-MMP-2 was investigated using gelatin zymography and shown to be elevated in tumors associated with lymph node metastasis (370). Increased expression of the MMP-2 activator, MT1-MMP, in carcinoma tissue and correlation with MMP-2 activity and distant metastasis were demonstrated using Northern blot. This suggests that activation of pro-MMP-2 by MT1-MMP may play an important role in determining papillary thyroid carcinoma metastasis. MMP-9, the other type IV collagenase able to degrade basement membrane in particular, does not appear to be important for thyroid cancer invasion (370, 371). In addition to the MMP system, the plasmin activation system proteolytic enzyme may lead to extracellular matrix degradation. An investigation of follicular thyroid carcinoma cell lines with metastases (FTC-236 and FTC-238) and without metastases (FTC-133) demonstrated that both the plasmin activation and MMP system were involved in matrix degradation, because inhibitors of both systems led to reduction in invasion (372) . The plasmin activation system is also important in generation of angiogenesis inhibitors, e.g., angiostatin (144). There are no data on the role of angiostatin in the thyroid.
D. Therapeutic application of angiogenesis inhibitors
The effects of therapy with carbimazole, propylthiouracil, or radioiodine on angiogenesis have not been studied; however, it has been known for many years that potassium iodide reduces thyroid gland vascularity before surgery, although the mechanism for this observation is unknown.
There is little information on the effect of therapy with antiangiogenesis agents. However, administration of TNP-470, a synthetic fumagillin analog, inhibited anaplastic thyroid cancer xenograft growth in nude mice with significant vasculature reduction (373) . This suggests a possible future therapeutic strategy for anaplastic thyroid carcinoma. An investigation of the antineoplastic effects of phenylacetate has shown inhibition of the growth of follicular thyroid cancer cell lines in vitro (374) . Phenylacetate inhibited VEGF secretion from the thyroid cancer cell lines, suggesting a potential therapeutic strategy in patients with differentiated thyroid cancer.
E. Genes and regulation of angiogenesis
Mutation of the tumor suppressor gene p53 is common in anaplastic thyroid cancer and, as shown in other tumor types, this leads to down-regulation of the angiogenesis inhibitor TSP1 with tumor dormancy and suppression of neovascularization (375, 376) .
The data summarized above demonstrate that angiogenesis is important in the pathogenesis of thyroid tumors. Thyroid tumors (in contrast to the pituitary) are more vascular than nontumorous thyroid tissue, and VEGF expression is higher. Although an inconsistent relationship is reported between vascular density and tumor behavior, there is a clear correlation between increasing VEGF expression and more aggressive tumor behavior. The association between the lymphatic angiogenic factors and papillary tumor metastasis and reduction in TSP-C and follicular tumor vascular spread may explain, in part, commonly observed differences in tumor behavior. The relatively common finding of an incidentally detected thyroid cancer (microcarcinoma), which does not progress to a clinically relevant cancer, may be due to absent angiogenesis. This is likely because the balance of angiogenesis favors inhibition of new vessel formation, which maintains the characteristic dormancy of the microtumor. A soluble VEGFR-3 or neutralizing antibodies to VEGF-C, VEGF-D, or VEGFR-3 may offer a potential low-toxicity strategy to the management for follicular thyroid cancer, and MMP-2 may in the future serve as a marker and therapeutic target for invasive or metastatic thyroid carcinoma.
VI. Parathyroid Tumors
Parathyroid tissue is unusual in that autotransplanted gland or hyperplasia induces neovascularization in vivo. Animal studies have suggested that parathyroid adenoma tissue stimulates angiogenesis in the rabbit iris model in vivo (377) and also in vitro (378) . Coculture of canine parathyroid gland led to a significant increase in microvessel density, which was not seen with injections of PTH or calcium alone (378) . The control and mechanism of the angiogenic switch in parathyroid tissue is not known.
Primary hyperparathyroidism arises due to the presence of adenomas in 80 -85% cases, carcinoma in 2-3%, and hyperplasia in the remainder of cases. The majority of cases are sporadic, but familial cases are associated with MEN 1 and MEN 2A, familial isolated hyperparathyroidism, and the hyperparathyroidism jaw tumor syndrome. Parathyroid tumors may also arise in chronic renal failure. Because of multigland involvement, it has been assumed that parathyroid tumors in chronic renal failure and parathyroid hyperplasia involve polyclonal cellular proliferations. X-chromosome inactivation analysis showed that seven of 11 (64%) patients with uraemic refractory hyperparathyroidism harbored at least one monoclonal parathyroid tumor and that monoclonality was demonstrable in six of 16 (38%) with primary parathyroid hyperplasia (379) . Another study has confirmed these findings in uraemic hyperparathyroidism, demonstrating a monoclonal pattern in 58% of hyperplastic nodules (380) . These studies suggest that monoclonal parathyroid neoplasms are common in uraemic hyperparathyroidism and parathyroid hyperplasia.
A. Microvascular density of tumors
The endothelial component of parathyroid glands was investigated using ultrastructural morphometry in six patients with MEN 1 and compared with six patients with uraemic hyperplastic glands (381) . The volume of capillaries and the number of capillaries per unit area were significantly higher in patients with MEN 1 compared with uraemic glands, suggesting increased vascular density in parathyroid glands removed from patients with MEN 1 compared with uraemic glands. It has previously been proposed that this may be related to elevated circulating FGF-2 found in the sera of these patients (381).
B. Angiogenic factors
VEGF.
There are no data available on the presence of VEGF in parathyroid tumors. An endothelial cell line has been established from human parathyroid tissue surgically removed from a patient with MEN 1, known as HPE (382) . FGF-2, VEGF, IGF-I, and ascorbic acid stimulate cell proliferation, whereas PTH was inert. TGF-␤ and heparin were inhibitory factors. Using PCR and restriction fragment length polymorphism, allelic loss was not evident at the MEN 1 locus on chromosome 11q12-13. It would be interesting to see further results regarding this potentially interesting tool.
FGF-2.
RT-PCR studies of FGF and receptors in parathyroid disease [normal, renal hyperparathyroidism (hyperplastic) and PT adenomas], demonstrated that FGF-R1 was present in all glands, and FGF-R2 was present in most glands (383) . FGF-1 and -2 were expressed in all samples with no correlation with disease type, whereas elevated FGF-3 levels were found in some diseased glands. Of potential importance, the FGF-3 gene (and FGF-2) is present on 11q13.3. There are no data on the potential role of FGF-4 or the newly described PTTG expression in parathyroid tumors.
A study comparing FGF-2 immunohistochemistry in hyperplastic parathyroid tissue derived from patients with MEN 1 and those without MEN 1 demonstrated the presence of FGF-2 in both groups, but more commonly in patients with MEN 1 (384) . Circulating FGF-2-like substance has been demonstrated in patients with MEN 1 (279), and circulating FGF-2 has been shown to increase clonal bovine endothelial cell proliferation (385).
IGF-I.
Parathyroid cells from adenomas and hyperplasia bind IGF-I, and cultured human parathyroid cells respond to IGF-I with increased IGF-I synthesis (386) . IGF-I and IGF-II stimulate bovine parathyroid cell growth in vitro (387) . There are no data, however, regarding a link between IGF-I and parathyroid vascularization or control of the angiogenic switch.
TGF-␣.
Cytoplasmic expression of TGF-␣ and its receptor, the EGF receptor, was demonstrated in parathyroid adenomas and surrounding normal tissue (388) . Others have demonstrated the presence of TGF-␣ mRNA and protein in parathyroid adenomas and hyperplasia, but not in normal parathyroid tissue (389) . This study also demonstrated the presence of EGF-R protein and mRNA in parathyroid adenomas, hyperplasia, and normal tissue (389) . EGF protein and mRNA were virtually undetectable. This may represent an important autocrine mechanism in parathyroid pathophysiology.
TGF-␣ stimulates proliferation of bovine parathyroid cells in culture and enhances proliferation associated with IGF-I or -II alone (387). EGF did not stimulate growth. The same group demonstrated the presence of EGF-R mRNA in parathyroid cancer, parathyroid hyperplasia, and less commonly parathyroid adenomas, but no immunoreactive EGF-R protein was detected due to either low receptor numbers or possible failure of transcription (390) . Whether TGF-␣ is linked to control of the angiogenic switch in the parathyroid gland is not known.
C. Matrix metalloproteinases
Although PTH regulates MMP-2 and MMP-9 (Table 2) in cultured osteoblasts and chondrocytes, thereby playing a potential role in matrix degradation allowing bone cell migration, there is no information on the role of MMPs in parathyroid tumor behavior.
D. Genes and regulation of angiogenesis
Loci associated with LOH in parathyroid tumors include 11q13 in both MEN 1 and also approximately one third of sporadic tumors (391) (392) (393) (394) . This locus (11q13) is also the site of the cyclin D1 gene (395), and rearrangements at this locus have been associated with D1 overexpression (396). Of potential relevance is the fact that the VEGF gene is also found at 11q13. It would be important to explore whether cyclin D1 overexpressing cells express more VEGF than quiescent cells.
Another site of LOH in 27% of sporadic parathyroid tumors is 1p35-36 (397). This locus is the position of p73, a new member of the p53 family, which has been mapped to 1p36. p73 Down-regulated VEGF gene expression by repression of the VEGF promoter and so reduced transcription (398). Two loci associated with vascular malformations (1p21-22 and 9p21) are also found to be associated with LOH in sporadic parathyroid tumors. The gene at 9p21, for example, causes ligand-independent activation of the endothelial cell-specific receptor tyrosine kinase Tie-2 (399). The relationship between these genetic changes and the angiogenic phenotype of parathyroid tumors has thus far not been studied. Clearly, these are huge loci with many genes, and the possible relationship between LOH and potential genetic changes linked with angiogenesis is speculative at present.
It is clear that when parathyroid tissue is autotransplanted, the angiogenic switch is activated. This process, however, appears to be carefully controlled because the majority of parathyroid tumors are benign and do not metastasize. The components of this delicately balanced mechanism are not known. PTH itself regulates bone VEGF and MMP expression. Whether there is a direct paracrine mechanism within the parathyroid gland itself is not clear. There are several possible genotype-angiogenic phenotype clues in parathyroid tumor pathogenesis that may further elucidate these mechanisms.
VII. Carcinoid Tumors
MVD has been investigated in a series (n ϭ 72) of lung carcinoid tumors using quantification of the vascular density of CD34-labeled endothelium at hot spots (400). This showed no relationship between angiogenesis assessed in this way and tumor metastasis, size, or histological type (atypical or typical). Immunohistochemistry for VEGF showed strong immunopositivity in midgut carcinoid tumor cells, whereas the protein is undetectable in stromal cells and endothelial cells (401). This may explain why conditioned medium from a human pancreatic carcinoid cell line led to stimulatory effects on both endothelial cells and fibroblasts (402). Tumor production of TGF-␣ or -␤ may also play a role in vascular proliferation in stromal cells adjacent to the tumor and the subsequent fibrosis characteristic of carcinoid syndrome due to matrix production (403, 404).
VIII. Gastrointestinal Neuroendocrine Tumors
VEGF is expressed in normal pancreatic islets, with upregulation occurring during tumor development in the transgenic mouse model of islet cell neoplasia (30). VEGFR-1 and VEGFR-2 are expressed in normal islets and in tumors but are not up-regulated during tumorigenesis. VEGF has been shown to stimulate islet cell proliferation and enhance insulin content (405, 406) . VEGF also colocalizes with insulin in pancreatic islet cells (407). Northern blot analysis of mRNA rodent insulinoma cell lines demonstrates VEGF mRNA and VEGF protein present in conditioned medium derived from a cell line using Western blot (407). Thus, it appears that VEGF may play an important paracrine role during both normal and neoplastic pancreatic islet cell proliferation and endocrine function.
Immunoreactive VEGF expression in 16 of 20 surgically removed neuroendocrine pancreatic tumors had no relationship between VEGF immunostaining and tumor stage (401). Tumor VEGF was located within neuroendocrine tumor cells. Neutralizing antibodies to VEGF reduced liver metastasis and tumor growth in a human neuroendocrine neoplasm transplanted to mice (408). These are preliminary data in an animal model, but they suggest a future therapeutic strategy.
Whether the angiogenic phenotype of carcinoids or other gastrointestinal neuroendocrine tumors allows for prognostic or therapeutic decision making is as yet unclear. The relationship between VEGF and other preangiogenic growth factors with endogenous and therapeutically administered substances known to inhibit angiogenesis such as octreotide and its analogs is not known. Further work is required on the potential of antiangiogenic strategies such as VEGF antibodies or MMP inhibitors in these tumors, which are more commonly malignant and less commonly cured by surgery alone.
IX. Conclusions
The relationship between angiogenesis and endocrine tumor behavior is yet to be fully explored. Although there are common features, tumors arising in different endocrine glands differ significantly in behavior and also in aspects of angiogenesis thus far studied. For example, pituitary tumors are less vascular than normal gland, whereas in the thyroid, hyperplasia and goiter as well as tumors are more vascular than normal thyroid. Malignant tumors are more common in thyroid and adrenal but very rare in the pituitary and parathyroid. Tumors are associated with genetic syndromes in the parathyroid and adrenal medulla, whereas they are more rarely associated with pituitary and thyroid tumors. With relevance to an understanding of angiogenesis, endocrine glands differ from nonendocrine tissue in their typically very vascular structures, with fenestrated endothelium and dependence for normal function in tight regulatory feedback loops requiring an excellent blood supply. Microtumors are commonly found in endocrine glands in which the vast majority will not increase in size. An understanding of the control of these tumors and the role of potential endogenous inhibitors of angiogenesis, e.g., 16-kDa PRL and somatostatin, will help with understanding the angiogenic balance. Although it is crucial that normal endocrine glands are vascular and have fenestrated vessels to allow easy hormone transfer across the endothelium, it is important that this is carefully regulated. The possible explanation of lack of activation of the angiogenic switch for common incidental tumors in pituitary, thyroid, and adrenal would be instructive in understanding the concept of tumor dormancy and would have potential implications for understanding tumor biology as well as possible therapy. The mechanism of the balance of angiogenesis and interaction with the extracellular matrix and MMPs may further advance the understanding of tumor invasiveness and patterns of invasion (vascular, bony, or lymphatic). The definition of genetic steps determining different angiogenic phenotypes and therefore tumor progression might increase our understanding of neoplastic progression and also allow measurement of markers of aggressive tumor behavior, initiation of appropriate therapy, and monitoring of tumor behavior. 
